Surmodics, Inc. SRDX demonstrated strong performance in the last reported quarter. Its loss per share was 51.9% narrower than the market estimate and sales beat the same by 8.3%. The strong ...
It has been about a month since the last earnings report for SurModics (SRDX). Shares have added about 4% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading ...
Mesothelioma is an aggressive tumor with a poor prognosis. Histological diagnosis of mesothelioma using limited tissue samples can be challenging. Carbonic anhydrase IX (CAIX) is a transmembrane ...
Tissue microarrays combines tens to hundreds of paraffin-embedded tissue cores into a single paraffin block. It is a practical and highly effective technique for high-throughput analyses of various ...
NEW YORK – The Consortium for Analytic Standardization (CASI) has unveiled its plan, funded by a $2 million grant from the National Cancer Institute, to standardize immunohistochemistry tests, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback